BlinkBio, Inc. Announces Issuance of U.S. Patent No. 9,931,407 Covering the Company’s Broadly Enabling SiLinker and Payload Cassette Technologies

Source:  BlinkBio, Inc. 4/25/18

Patent Establishes Strong Foundational Intellectual Property for BlinkBio’s Proprietary Candidates Advancing toward Clinical Testing

BlinkBio Inc., a privately held biotechnology company, today announced that the USPTO issued patent no. US 9,931,407 covering BlinkBio’s SiLinker and Payload Cassette technologies, primary components of the Company’s Tunable Drug Conjugate (TDC) Platform. TDCs represent an innovative approach to the development of differentiated Drug Conjugate therapies for the treatment of cancer and other diseases. The Company is rapidly advancing its preclinical pipeline based on this novel platform and expects to complete its first IND filing by mid-2019.

“We are delighted with the issuance of this key patent for technologies innovated internally by BlinkBio scientists,” stated Dr. Colin Goddard, Chairman and CEO of BlinkBio. “Our SiLinkers constitute a tunable, pH sensitive, linker technology that we can employ in TDCs to enable rapid and uniform release of potent toxins inside targeted tumors. Further, our Payload Cassette technology allows delivery of multiple payloads per TDC, enabling high concentrations of a cytotoxic agent within the tumor. Because of these and other key capabilities, we believe our TDC platform represents a highly competitive alternative to conventional Antibody Drug Conjugates (ADCs).”

Drug Conjugate therapies have become an increasingly important part of the therapeutic arsenal available to oncologists, using a targeting moiety to selectively deliver cytotoxins to cancer cells with the potential to improve safety and efficacy compared to traditional cytotoxic chemotherapy. BlinkBio’s next-generation TDCs utilize rapidly cleaving SiLinkers that can deliver multiple Conditionally Active Payloads (CAPs) (organized in Payload Cassettes) in order to concentrate high doses of toxin inside the targeted tumor, while largely protecting normal cells from toxicity. Since our TDCs are <1/15^th the size of conventional ADCs, they also can achieve better tumor penetration and more rapid clearance compared to ADCs. Furthermore, the tunability of the patented SiLinker system allows BlinkBio to make slowly cleaving drug conjugates as well, further expanding the technology to applications typically addressed by conventional ADC approaches.

About BlinkBio Inc.
BlinkBio is a privately held, biotechnology company based in Jupiter, FL, that is advancing Tunable Drug Conjugates (TDCs), a new class of drug conjugate therapies, for the treatment of cancer and other diseases. We have designed our TDCs around our broadly enabling, proprietary SiLinker and Payload Cassette technologies. Our lead therapeutic program targets the Folate Receptor alpha (FRα), a cell surface receptor that is highly overexpressed in a high proportion of ovarian, endometrial, and non-small cell lung cancer (NSCLC). Using a small molecule ligand, rapidly cleaving SiLinkers and Conditionally Active Payloads (CAPs) organized into Payload Cassettes, we have validated the performance of all elements of our TDC platform and are currently finalizing the selection of a development candidate in this program. We expect our first TDC to enter the clinic in mid-2019.

BlinkBio Inc. Announces Exclusive Agreement with The Scripps Research Institute Providing Targeting Technology for Use in BlinkBio’s Tunable Drug Conjugates Platform

Source:  BlinkBio, Inc. 11/10/16

BlinkBio Inc., a biotechnology company advancing Tunable Drug Conjugates (TDCs) for cancer and other diseases, today announced the signing of an exclusive option agreement to license Dual Variable Domain-Fab (DVD-Fab) technology developed in the laboratories of Dr. Christoph Rader and Dr. William R. Roush at The Scripps Research Institute (TSRI) in Jupiter, FL. The technology comprises engineered antibody fragments that include regions of antibodies that recognize target proteins they are designed to bind, together with elements that allow the DVD-Fabs to connect to BlinkBio’s proprietary TDCs.


“BlinkBio is developing TDCs that can rapidly release high concentrations of therapeutic payloads inside cancer cells, following which the TDC molecules are designed to be cleared from the body within hours, thereby delivering a strong therapeutic benefit while minimizing side effects,” stated Colin Goddard, Ph.D., Chairman and CEO of BlinkBio. “The addition of the Scripps’ targeting technology is a major step forward for BlinkBio, potentially allowing us to address any cell surface protein against which an antibody can be raised.”

During the option period BlinkBio will provide sponsored research funding to the Rader and Roush laboratories, and the BlinkBio and TSRI teams will collaborate on research projects to confirm the feasibility of using the two technology platforms in combination. BlinkBio and the Rader lab are both located within TSRI’s Florida campus, offering optimal opportunities for collaboration. Further collaborative projects are planned following the execution of the full license, including the generation of DVD-Fab TDC drug candidates and exploring the ability of TDCs to deliver multiple and different payloads within a single DVD-Fab TDC. The parties expect the full license to be executed within a year. Additional terms of the agreement were not provided.

“We are pleased to partner with BlinkBio in developing a promising new approach that we hope will result in more precisely targeted cancer therapeutics,” said TSRI Chief Operating Officer Richard King. “At Scripps Florida, we are committed to advancing science for the benefit of human health while supporting the region’s emerging biotech cluster.”

About BlinkBio Inc. and the Tunable Drug Conjugate (TDC) Platform
BlinkBio is a biotechnology company formed to exploit Bioorthogonal Linker (“BLink”) chemistries in our Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases. The development of antibody (ADC) and small molecule (SMDC) drug conjugates has already provided a valuable contribution to the treatment of cancer by enabling the targeted delivery of therapeutic “payloads” inside cancer cells. However, there remains room for improvement. For example, ADCs can stay in the body for many days, creating a need for stable linkers to limit toxic side effects from systemic release of payloads, and there are challenges in making multi-payload SMDCs.

At BlinkBio, we have assembled a proprietary suite of assets for the development of Tunable Drug Conjugates (TDCs) that use a differentiated rapid payload release/rapid systemic clearance approach to drive high payload concentrations within tumor cells while minimizing toxicities to patients. The Company has deployed proprietary silicon-based linker chemistries to create a unique SiLinker and Payload Cassette platform for incorporation into our TDCs. The licensing of the DVD-Fab targeting capability from The Scripps Research Institute (TSRI) provides a proprietary means of specifically binding a broad array of cell surface proteins with the aim of delivering powerful anti-cancer medicines inside the tumor cell and within the tumor microenvironment. DVD-Fab containing TDCs are also expected to be cleared from the body within hours, enabling better management of side effects.

BlinkBio’s business strategy is focused on developing selected TDCs through clinical development, while seeking partnerships with major pharmaceutical and biotech companies to broaden the utility and application of these novel drug conjugates in improving treatment outcomes for patients worldwide. The Company is located within The Scripps Research Institute (TSRI) in Jupiter, Florida.

Medicine Man Technologies, Inc. announces launch of direct operator division of licensed cannabis operations

Source:  Medicine Man Technologies, Inc. 1/17/19

Today Medicine Man Technologies (OTCQX: MDCL), a leading consulting, intellectual property licensing and products company in the cannabis industry, has announced a binding agreement that is expected to lead to the near-term acquisition of the Colorado licensee, Medicine Man Denver (MMD). MMD is one of the pioneering operators that helped establish the burgeoning cannabis industry over the past decade, with brand recognition far beyond its immediate market.  Its operations include one of the largest indoor cultivations in the state of Colorado as well as four retail locations with combined sales that have kept it in the top tier of operators in the state.

MDCL plans to pursue other acquisitions and partnerships with similar, mature industry leading operators, in the birth place of the legal cannabis industry and beyond

These planned and prospective transactions are helping to realize the promise of MDCL's vision to establish an industry-leading, fully-integrated cannabis company that delivers resources to entrepreneurs in the industry and soon, products to consumers. 

"Building upon MMT's established expertise as consultants that have helped win licenses and establish operations in 17 states with over 100 clients, these moves are keeping the promise of Medicine Man Technologies' vision to become an operator in this space," says Andy Williams, Medicine Man Technologies' Chief Executive Officer.  "Once officially brought into the fold, MDCL's annual revenue run rate will exceed $40 million.  We couldn't be more excited about what the future holds."

Because MMD is a holder of cannabis licenses issued by the Marijuana Enforcement Division (MED) in the State of Colorado, the acquisition of MMD will require the passing of the currently-introduced Colorado HB19-1090 (https://leg.colorado.gov/bills/hb19-1090) which is currently working its way through the legislature, with support of the current governor.  If HB19-1090 becomes law, it will allow for public company ownership of Colorado-licensed cannabis businesses.

The final acquisition will require the approval of the MED, as well as local city and county rules concerning the transfer and sale of ownership interest.  Due to current legal restrictions, rather than acquiring a direct right to purchase the entity, MDCL has agreed to license MMD's company brand globally and issue warrants that can only be exercised by the exchange of equity of MMD for common stock of MDCL at an agreed upon value subject to approval by the MED and the warrant holders electing to exercise.

MDCL had previously disclosed in its SEC filings of its intent to acquire MMD, as several persons connected to MDCL are also owners of MMD, including Andy Williams, current CEO of MDCL. MDCL has obtained independent valuations of the entities to be acquired. The relevant term sheet provides that the value of the shares to be issued to each owner of the entities to be acquired shall be consistent with these independent valuations.

About Medicine Man Technologies, Inc.
Established in March 2014, the Company secured its first client/licensee in April 2014. To date, the Company has provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. The Company currently has or has had active clients in California, Iowa, Oregon, Colorado, Nevada, Illinois, Michigan, Arkansas, Pennsylvania, Florida, Ohio, Maryland, New York, Oklahoma, Massachusetts, Puerto Rico, Canada, Australia, Germany, and South Africa. The Company continues to focus on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company's highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will "share" the ever-improving experience and knowledge of the network, and 5) continuing the expansion of our Brands Warehouse concept through entry into industry based cooperative agreements and pursuing other acquisitions as they prove suitable to our overall business development strategy.

Medicine Man Technologies Announces Andy Williams as Interim CEO

Source:  Medicine Man Technologies, Inc. 12/4/18

Paul Dickman named Chairperson of the Board

Medicine Man Technologies Inc. (OTCQX: MDCL) ("Medicine Man Technologies" or "Company"), one of the United States' leading cannabis branding and consulting companies, today announced Co-founder Andy Williams has been named Interim CEO of Medicine Man Technologies. While assuming the role as Interim CEO, Mr. Williams has stepped down as Chairperson of the Board. Paul Dickman has been appointed by the Company's Board of Directors as Chairperson of the Board and Secretary for Medicine Man Technologies.  Mr. Williams will serve as Interim CEO until a permanent CEO is named.

Paul Dickman, Chairperson of the Board for Medicine Man Technologies commented, "As a Co-founder of Medicine Man Technologies, Andy has demonstrated a proven ability to lead this organization and drive shareholder value. His insight and knowledge of the cannabis industry has been extremely valuable to the Board and the Company and we are confident he is the right person for this important role at this time. We are grateful he has accepted this commitment and look forward to his success as Interim CEO."

"Brett Roper was an influencer in the cannabis industry and helped grow Medicine Man Technologies into an industry leader. He helped build our Company to where it is today and we are forever grateful for his service and the leadership he provided," commented Andy Williams. "As Interim CEO, I look forward to continue working closely with the Board as well as our team at Medicine Man Technologies to serve our expanding client base and execute on our growth strategy as we prepare for our next phase."

Andy Williams is among America's most pioneering thought leaders and entrepreneurs in the legal cannabis space.  As co-founder and CEO of celebrated retail cannabis chain Medicine Man, Mr. Williams has already fulfilled his vision of becoming "the Costco of marijuana." As co-founder and former chairperson of the board of industry-leading consultancy Medicine Man Technologies, Mr. Williams has expanded his influence exponentially—helping entrepreneurs in other states via his extensive cultivation expertise and unparalleled business acumen. Mr. Williams is also a founding partner in phytopharmaceutical company MedPharm and is investing heavily into the future of pharmaceutical-grade cannabis research.

With years of experience in the world's first regulated market, Mr. Williams is a leading expert on the cannabis industry featured in The New York Times, Rolling Stone, CNN, The Wall Street Journal, BBC and the MSNBC docu-series "Pot Barons," which focused on Mr. Williams as one of the show's central characters.

Mr. Williams continues to elevate his politically active leadership in the ever-expanding marijuana industry, working daily to protect and grow the cannabis industry as a board member with the Cannabis Trade Federation, which works federally on tax reform and other industry-specific issues, and Colorado Leads, a pro-growth organization focusing its efforts locally.
Paul Dickman is the Founder & Principal of Breakwater MB, a boutique merchant bank focused on providing the expertise and funding needed for cannabis-focused organizations to transition into the public market.  Mr. Dickman currently serves as the CFO of a publicly-traded company with operations in Los Angeles, New York, and Shanghai. His areas of expertise include corporate finance, capital markets, and corporate governance.

Prior to founding Breakwater MB, Mr. Dickman founded Breakwater Corporate Finance, a professional services agency offering outsourced CFO and board governance services to private and micro-cap public companies. Through Breakwater Corporate Finance, Mr. Dickman has helped organizations raise multiple rounds of equity and debt capital and has facilitated several public offerings while providing profitable liquidly events for investors.

Mr. Dickman was the founding CFO of Medicine Man Technologies and assisted the Company through the process of becoming a publicly traded entity.  Once public, Mr. Dickman's replacement was hired and he moved to serve on the board of directors.

Mr. Dickman has sat on the Board of Directors for Rockies Venture Club, Medicine Man Technologies, and Chineseinvestors.com, Inc. He possesses a Bachelor's Degree in Finance and Accounting, is a licensed CPA, and is a Fellow of the National Association of Corporate Directors (NACD).

About Medicine Man Technologies, Inc.
Established in March 2014, the Company secured its first client/licensee in April 2014. To date, the Company has provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. The Company currently has or has had active clients in California, Iowa, Oregon, Colorado, Nevada, Illinois, Michigan, Arkansas, Pennsylvania, Florida, Ohio, Maryland, New York, Oklahoma, Massachusetts, Puerto Rico, Canada, Australia, Germany, and South Africa. We continue to focus on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company's highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will "share" the ever-improving experience and knowledge of the network, and 5) continuing the expansion of our Brands Warehouse concept through entry into industry based cooperative agreements and pursuing other acquisitions as they prove suitable to our overall business development strategy.

SilverCrest Metals Announces Executive Appointments and Provides Corporate Updates

Source:  SilverCrest Metals, Inc. 1/14/19

SilverCrest Metals Inc. (TSXV: SIL) (NYSE American: SILV) ("SilverCrest" or the "Company") is pleased to announce the promotions of Stephany ("Rosy") Fier to the position of Vice President, Exploration & Technical Services and Nicholas Campbell as Executive Vice President, Business Development for the Company.

Ms. Fier is a mining and geological engineer with more than 10 years' experience in exploration, construction and mine production in Mexico, Canada, USA, and Central America. She has been the Exploration Manager for the Company since its inception in 2015 and has lead the SilverCrest team in the discovery of a high-grade precious metal vein system at the Las Chispas Property. Previously, Ms. Fier held several roles with SilverCrest Mines Inc. at the Santa Elena Mine in Sonora, Mexico, from 2009 to 2015. These roles included exploration manager, resource modeller, construction supervisor, and production engineer for both open pit and underground mining.

Mr. Campbell has been the Vice President, Business Development for the Company since October 2016 and has been promoted to Executive Vice President, Business Development.

Michael Rapsch has resigned from his position as Vice President, Corporate Communication.
N. Eric Fier, CPG, P.Eng comments, "The promotions of both Rosy and Nick are a testament to their hard work over the last three years to help make SilverCrest another success story in the industry. Congratulations to them and their dedication. The Company sincerely thanks Mr. Rapsch for his contributions and services and wishes him the best in his future endeavours."

OTHER CORPORATE UPDATES
An online web-based platform called "VRIFY" has completed a virtual tour of Las Chispas, which is available on the homepage of the Company's website, www.silvercrestmetals.com.
SilverCrest will be presenting at the upcoming Vancouver Resource Investment Conference 2019 on January 20 to 21 and the AME's Mineral Exploration Roundup 2019 conference in Vancouver on January 31. Various intercepts, including those of Record Hole BA18-122 (9.3 metres grading 6,336 gpt AgEq) recently announced on January 9, 2019, will be on display in the Core Shack at Roundup.

ABOUT SILVERCREST METALS INC.
SilverCrest is a Canadian precious metals exploration company headquartered in Vancouver, BC, that is focused on new discoveries, value-added acquisitions and targeting production in Mexico's historic precious metal districts. The Company's current focus is on the high-grade, historic Las Chispas mining district in Sonora, Mexico. SilverCrest is the first company to successfully drill-test the historic Las Chispas Project resulting in numerous discoveries. The Company is led by a proven management team in all aspects of the precious metals mining sector, including taking projects through discovery, finance, on time and on budget construction, and production.

SilverCrest Announces Additional High-Grade Results at Las Chispas, Including Record Drill Hole Intercept; 9.3 Metres (True Width) at 6,336 gpt AgEq

Source:  SilverCrest Metals, Inc. 1/9/19

SilverCrest Metals Inc. (“SilverCrest” or the “Company”) is pleased to announce further Phase III in-fill drill results for the Las Chispas Property (the “Property”) located in Sonora, Mexico. The current drill program is designed to increase resources through expansion drilling and improve confidence in the resource with closely spaced in-fill drilling in the Babicanora Vein. The 20 reported in-fill holes in this release were targeting mineralization in the high-grade Area 51 zone (13 holes), Babicanora Central zone (7 holes), and Babicanora Footwall (“FW”) and Hangingwall (“HW”) veins which were drilled while targeting other zones. Combined with the 19 in-fill drill results previously reported on November 1, 2018 and December 13, 2018, the in-fill drilling program has returned very positive results. A total of 39 in-fill holes have been completed with 28 holes in the Area 51 zone. The weighted average (true width, uncut, undiluted) of the 28 in-fill holes from Area 51 is 3.9 metres grading 11.36 gpt gold (or “Au”) and 1,064.1 gpt silver (or “Ag”), or 1,915 gpt silver equivalent (“AgEq”, based on assumptions defined in table below). For comparison, in the September 13, 2018 resource estimate, Area 51 had an estimated weighted average true width of 2.7 metres, grading 7.13 gpt gold and 614 gpt silver or 1,148 gpt AgEq. Hole BA18-122 intersected and expanded high-grade mineralization in Area 51’s “Shoot 43” returning an impressive 9.3-metre wide intercept grading 6,336 gpt AgEq compared to previously modelled narrower mineralization in this area, which had averaged 3 metres in true width (see attached Figures).

N. Eric Fier, CPG, P.Eng, and CEO, remarked, “Drill Hole BA18-122 is for the record books with 9.3 metres (true width) grading 6,336 gpt AgEq (84.5 gpt AuEq). Further positive results from closely spaced in-fill drilling continue to confirm the continuity of high-grade mineralization in the Babicanora Vein, including Area 51 and Babicanora Central zones, as well as the Babicanora FW and HW veins. Additional drill holes in Area 51 are indicating wider mineralized thicknesses in several areas than previously modelled and are identifying discrete multi-kilogram per tonne silver equivalent mineralized shoots (Shoots 43 and 51). These additional core holes are critical to both in-fill confirmation and potential expansion of resources in the Babicanora veins. This is a great way to start the New Year as we continue to improve our confidence and add ounces in Area 51, hunt for new discoveries on the additional 22 known veins not in the September 2018 resource estimate, compile the new drill results for the next updated resource, and advance the Las Chispas Preliminary Economic Assessment.”

The most significant result for this release in is Hole BA18-122 which intersected 9.3 metres (estimated true width) grading 39.66 gpt Au and 3,361.0 gpt Ag, or 6,336 gpt AgEq (84.5 gpt AuEq). Also noteworthy are holes BA18-116, at 2.4 metres grading 4.30 gpt Au and 1,571.5 gpt Ag, or 1,894 gpt AgEq, and BA18-114 at 3.0 metres grading 5.37 gpt Au and 998.0 gpt Ag, or 1,401 gpt AgEq. The following table summarizes the most significant drill intercepts (uncut, undiluted) for this release;

Babicanora Vein (Area 51 zone) In-Fill Drill Intercepts:

Hole No.§	From (m)	To (m)	Drilled Intercept (m)	Est. True Width (m)	Au gpt	Ag gpt	AgEq* gpt
BA18-110	370.0	373.6	3.7	3.3	3.72	450.5	730
incl.	373.1	373.6	0.6	0.5	14.55	1,640.0	2,731
BA18-112	205.9	206.6	0.7	0.6	0.65	174.0	223
BA18-113	137.2	140.4	3.3	2.9	1.08	365.0	445
BA18-114	289.0	293.2	4.2	3.0	5.37	998.0	1,401
incl.	291.1	292.2	1.1	0.8	11.95	1,860.0	2,756
	309.1	311.2	2.1	1.5	2.49	225.7	413
BA18-115	172.7	177.4	4.7	4.3	0.73	149.0	204
BA18-116	318.9	321.6	2.8	2.4	4.30	1,571.5	1,894
incl.	320.0	320.8	0.8	0.7	6.38	4,160.0	4,639
BA18-118	219.6	226.1	6.5	4.0	0.50	211.0	249
BA18-119	351.8	352.3	0.5	0.4	0.78	106.0	164
	362.6	364.1	1.5	1.2	5.44	774.3	1,182
BA18-120	185.8	195.0	9.2	8.6	0.98	409.1	483
BA18-122	194.3	207.5	13.2	9.3	39.66	3,361.0	6,336
incl.	194.3	194.8	0.5	0.4	252.00	9,740.0	28,640
incl.	198.9	200.2	1.3	0.9	92.70	7,570.0	14,522
incl.	205.4	206.0	0.6	0.4	47.30	7,760.0	11,307
	224.8	226.8	1.9	1.4	6.01	722.4	1,173

Babicanora Vein (Babicanora Central zone) In-Fill Drill Intercepts:

Hole No.§	From (m)	To (m)	Drilled Intercept (m)	Est. True Width (m)	Au gpt	Ag gpt	AgEq* gpt
UB18-16	21.1	21.6	0.5	0.4	2.05	5.0	159
UB18-17	66.6	75.5	8.9	6.3	0.21	330.3	346
UB18-18	70.8	73.7	2.9	2.6	9.84	235.7	974
UB18-20	91.5	93.0	1.5	1.0	2.73	40.3	245
UB18-21	39.8	48.0	8.3	7.8	0.95	407.8	479
incl.	46.5	48.0	1.5	1.4	0.14	1,917.0	1,928
UB18-22	48.0	57.0	9.0	9.0	2.09	352.5	509
incl.	49.5	51.0	1.5	1.5	1.90	933.0	1,076
UB18-23	37.1	51.0	13.9	13.9	1.42	207.6	314
incl.	50.0	51.0	1.0	1.0	16.40	349.0	1,579

Babicanora FW Vein In-Fill Drill Intercepts:

Hole No.§	From (m)	To (m)	Drilled Intercept (m)	Est. True Width (m)	Au gpt	Ag gpt	AgEq* gpt
BA18-115	208.7	209.2	0.5	0.5	9.81	935.0	1,671
BA18-120	225.5	226.0	0.5	0.5	0.98	409.1	483
UB18-14‡	34.0	36.0	2.0	1.0	1.21	143.1	234
UB18-18	5.1	6.2	1.1	1.0	1.59	127.7	247
UB18-19	3.5	6.0	2.5	2.3	1.26	52.2	146
UB18-20	10.3	11.4	1.1	0.7	0.79	89.6	149
UB18-21	9.5	10.0	0.5	0.5	25.90	2,010.0	3,952
UB18-22	13.3	16.1	2.8	2.8	1.61	35.1	156

Babicanora HW Vein In-Fill Drill Intercepts:

Hole No.§	From (m)	To (m)	Drilled Intercept (m)	Est. True Width (m)	Au gpt	Ag gpt	AgEq* gpt
BA18-110	342.4	342.9	0.5	0.4	2.88	270.0	486
BA18-116	300.8	301.4	0.6	0.5	1.72	152.0	281
UB-18-23	79.3	80.6	1.3	1.3	0.05	167.0	171

Note: all numbers are rounded.
* AgEq based on 75 (Ag):1 (Au) calculated using long-term silver and gold prices of US$18.50 per ounce silver and US$1,225 per ounce gold, with average metallurgical recoveries of 86.6% silver and 98.9% gold.
§ UB signifies an underground core hole. BA is a surface core hole.
‡Drill intercept related to Babicanora Central zone was previously reported on November 1, 2018.

All assays were completed by ALS Chemex in Hermosillo, Mexico, and North Vancouver, BC, Canada. Holes BA18-111, BA18-117, and BA18-121 were below the Company’s cutoff grade of 150 gpt AgEq within the Babicanora veins. Holes BA18-117 and 121 are located at the top of the high-grade footprint with minimal impact on estimated resources. Hole BA18-111 is located in a previously define lower grade resource area (see attached Figures).

Mineralization in Hole BA18-122 shows epithermal silica and sulfide textures, including colloform-banding, jigsaw, cockade and crustiform that are commonly found in an epithermal Precious Metal Zone. The highest-grade intervals in this hole are related to both primary (argentite) and secondary (acanthite and polybasite) silver sulfides, electrum and native gold.

In-fill drill results for the northwest projection of the Babicanora Vein (Babicanora Central zone), Babicanora FW Vein and Babicanora HW Vein confirm estimated grade and width continuity as previously presented in the September 2018 resource estimate.

The Company continues its Phase III exploration program with nine drills operating on site. Drills are focused on expanding mineralization for inclusion in the next updated resource estimate anticipated in Q1, 2019 and in-fill drilling (estimated 25 metre spacing) to reclassify Inferred Resources to Measured and Indicated. An additional 5,000 to 10,000 metres of drilling are planned for inclusion in the next updated resource. Other ongoing site work includes PEA study, ground breaking for the Area 51 decline, an extensive metallurgical test program, drilling large diameter wells for site water, and permitting for various additional work.

The Qualified Person under National Instrument 43-101 Standards of Disclosure for Mineral Projects for this news release is N. Eric Fier, CPG, P.Eng, and CEO for SilverCrest, who has reviewed and approved its contents.

ABOUT SILVERCREST METALS INC.
SilverCrest is a Canadian precious metals exploration company headquartered in Vancouver, BC, that is focused on new discoveries, value-added acquisitions and targeting production in Mexico’s historic precious metal districts. The Company’s current focus is on the high-grade, historic Las Chispas mining district in Sonora, Mexico. SilverCrest is the first company to successfully drill-test the historic Las Chispas Project resulting in numerous discoveries. The Company is led by a proven management team in all aspects of the precious metal mining sector, including taking projects through discovery, finance, on time and on budget construction, and production. 

Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US

Source:  Emerald Health Therapeutics, Inc. 1/29/19

Emerald Health Therapeutics and Emerald Health Naturals on track to launch endocannabinoid-supporting products in Canada

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019.  The joint venture, called Emerald Health Naturals (“EHN”), secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.

In December 2018, EHT received natural product numbers (NPNs) from Health Canada to sell Endo in Canada. EHN is owned 51% by Emerald and 49% by EHB.

“For the Endo products to be embraced by retailers with such high standards of retail excellence and broad reach like Whole Foods Market in the US is an important milestone for this unique natural health supplement line,” said Gaetano Morello, ND, CEO of Emerald Health Naturals. “A non-cannabis product line capable of nurturing the endocannabinoid system is a unique product category - and it is one that is garnering significant attention in the US. We aim to similarly build strong distribution channels with top retailers in Canada in 2019.”

“With 60% of cannabis users also being users of natural health products, we have a two-pronged opportunity in Canada to build a stand-alone market for the Endo product line for cannabis non-users as well as achieve Emerald brand recognition among cannabis users in channels unable to carry cannabis products,” said Avtar Dhillon, President and Executive Chairman, Emerald Health Therapeutics. “Natural health product stores, pharmacies, and even grocery stores may all be potential outlets for the Endo product line. We look forward to offering the proprietary Endo products to Canadian consumers this year.”

Endo nutritional supplements feature PhytoCann-Complex™, a proprietary formulation consisting of non-cannabis, non-psychoactive, plant-based bioactive compounds that support the body’s endocannabinoid system. The role of the ECS as the body’s innate balancing mechanism is key to the regulation of everything from appetite, energy, metabolism, fertility and immunity to sleep, mood, pain perception and memory.  The Endo product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss and Endo Inflame, and they are intended to naturally address the body’s response to conditions such as stress, anxiety, restless sleep and pain, and foster overall health and wellness.

Over the last year, EHB has secured multiple distribution and sales channels for the Endo product line in the United States and internationally, ranging from small independent natural health product retailers to nationwide grocery store chains like Whole Foods Market, as well as Amazon.com.

About The Endo Product Line*

Endo Brain - Naturally supports mental acuity and cognition by nurturing and nourishing your endocannabinoid system.

Endo Sleep - Enjoy restful and rejuvenating sleep by naturally supporting your endocannabinoid system, optimal health and vitality.

Endo Calm - Naturally address your body’s response to stress and anxiety by supporting your endocannabinoid system and optimal health and vitality.

Endo Bliss - Naturally supports a positive outlook and resistance to daily pressures by nurturing and nourishing your endocannabinoid system.

Endo Inflame - Naturally promote your body’s healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.

* The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

 

Emerald Health Therapeutics Closes Emerald Health Naturals Joint Venture

Source:  Emerald Health Therapeutics, Inc. 1/10/19

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).

Emerald has invested $5,000,000 for 51% equity ownership of EHN. EHB has granted EHN the exclusive Canadian distribution rights to EHB’s award-winning product line in exchange for 49% equity ownership of EHN. EHB’s product line consists of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.

Market research commissioned by the Company identified that approximately 60% of legal cannabis users also use natural health products. This strong consumer overlap between the two markets is expected to create a unique opportunity for Emerald to build its health brand through EHN and begin sales of endocannabinoid-supporting products in natural health product channels. These channels are not authorized to sell cannabis under the Canadian federal cannabis regulations for recreational use which came into force on October 17, 2018. However, if these channels are approved in the future, the Company expects to be well positioned to introduce its cannabis-based products into these channels.

The formation of the Joint Venture is a “related-party transaction” as such term is defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”) as EHB is approximately 71% owned by Emerald Health Sciences Inc., which is also the holder of approximately 30.6% of the outstanding common shares of the Company. The Company is relying on the exemption from the formal valuation requirements of MI 61-101 set out in Section 5.5(b) of MI 61-101 and the exemption from the minority shareholder approval requirements of MI 61-101 set out in Section 5.7(a) of MI 61-101 in respect to the creation of the Joint Venture.

In connection with the formation of the Joint Venture, EHN has also acquired the assets of GAB Innovations (“GAB”) and has granted non-exclusive sub-distribution rights to Avricore Pharmaceuticals Inc. (formerly VANC Pharmaceuticals Inc.) (“Avricore”). Both GAB and Avricore have established networks and a history of sales success in the natural health product and pharmacy channels. Gaetano Morello, ND, the founder of GAB, has been appointed CEO of EHN.

Emerald also announces that Chris Wagner has resigned as a director of the Company. As previously announced, Mr. Wagner stepped down as CEO effective November 28, 2018. Mr. Wagner will continue to act as a consultant to Emerald and provide assistance when needed.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Agro-Biotech operation in Québec is completing its 75,000 square feet indoor facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System

Source:  Emerald Health Therapeutics, Inc. 12/4/18

Emerald Health Therapeutics Inc. ("Emerald" or “the Company”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients. EHN intends to launch the Endo product line over-the-counter in Canadian natural health product, grocery, and pharmacy stores by mid-2019.

“Our Endo product line was developed by internationally recognized natural health product experts and is unique in the natural healthcare marketplace. We are very excited to be able to offer our Endo products to Canadian consumers to support their endocannabinoid systems and improve aspects of their health,” said Dr. Gaetano Morello, CEO of EHN. “We are leveraging our key strategic relationships and working hard on the marketing, manufacturing and logistical steps in order to launch the Endo line by mid-2019.”

The Endo product line was developed by Emerald’s joint venture partner, San Diego-based Emerald Health Bioceuticals, Inc. (“EHB”), and its scientific advisors. Over the last year, EHB has secured multiple distribution and sales channels in the United States and internationally for the Endo product line, ranging from small independent natural health product retailers to nation-wide grocery store chains and Amazon.com. EHN, which is owned 51% by Emerald and 49% by EHB, will have exclusive Canadian distribution rights to the Endo products.

These cannabis-free nutritional supplements feature PhytoCann-Complex™, a proprietary formulation designed to support the body’s endocannabinoid system, which plays a central role in the orchestration, maintenance, and balance of health and well-being. The products include Endo Sleep^TM, Endo Inflame^TM, Endo Brain^TM, Endo Bliss^TM, and Endo Calm^TM. Endo Brain was recently awarded a prestigious 2018 SupplySide Consumer Packaged Goods Editor’s Choice Award for Brain Health, building on its NEXTY "Editor's Choice" Best New Supplement Award in the natural products industry in 2017.

“We have the unique opportunity to brand Emerald through EHN’s offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “In the event that CBD and other non-psychoactive cannabinoid products are allowed to be sold in these channels in the future, Emerald will be well positioned to add its cannabinoid compounds to the Endo product line and leverage its early marketing advantage. Emerald’s vision is to enhance human health through cannabis science. The creation of EHN and the launch of the Endo product line in Canada are key steps in Emerald’s strategy to achieve this goal.”

As announced in the Company’s press release dated November 22, 2018, the Company has obtained conditional approval of the TSX Venture Exchange for the formation of the EHN joint venture. The parties are in the process of finalizing definitive documentation with respect to EHN. Formation of EHN is conditional upon final regulatory approval and settlement of definitive documentation.

About the Endocannabinoid System

The endocannabinoid system (“ECS”) is a biological system with a vital role in regulating human health and disease. A lack of balance in the endocannabinoid system is likely to have adverse consequences in a number of human health conditions. The ECS is activated by endocannabinoids produced naturally in the body, but also by cannabis or non-cannabis plant ingredients that mimic the actions of cannabinoids produced in the body. All products in the Endo product line contain Phyto-Cann^TM Complex, which has been formulated by leading nutritional and cannabinoid scientists with non-cannabis herbal and botanical cannabinoids designed to favorably impact the ECS.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acres) greenhouse in the Lower Mainland to cultivate cannabis and its Agro-Biotech operation in Québec is currently operating out of its 75,000 square feet indoor cannabis cultivation facility. Commercial production is expanding in both facilities. In addition, Emerald has secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol out of its hemp harvest. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald, EHN and EHB are all part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Emerald Health Therapeutics Files 17 Patent Applications Covering Defined Dose™ Cannabis Products

Source:  Emerald Health Therapeutics, Inc. 10/16/18

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.  The products provide more precise and consistent delivery, dosage, and formulations. Defined Dose™ cannabis products will, when made available to the public, provide consumers with products currently not available.

The seventeen Defined Dose™ cannabis patent applications relate to:

• Inhaled dosage forms for smoking
• Inhaled dosage forms for vaping; and
• Capsule and edible formulations and dosage forms based on a novel understanding of cannabinoid molecular pathways and how they influence disease mechanisms.

Certain of the Defined Dose™ cannabis products are eligible for launch in Canada under existing Canadian regulations. Others are expected to be eligible under anticipated regulatory changes in 2019.

“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science. Emerald’s filing of these patent applications is an important step,” said Chris Wagner, CEO of Emerald. “Our expanding research and development effort is focused on internal facilities and staff as well as forming key relationships with other cannabis research experts, such as our recently announced agreement with VivaCell Biotechologies Espana.”

“Emerald’s intent is to be at the forefront of understanding the mechanism of action of the endocannabinoid system and developing proprietary products that enable both medical and adult-use consumers to achieve measured outcomes with well characterized, reliable products,” said Avtar Dhillion MD, Executive Chairman of Emerald. “Our aim is to produce a product pipeline of next-wave cannabis products that fit the better-defined needs and preferences of consumers as Canada and other countries that legalize medical and recreational cannabis use.”

Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most important "first to file" jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids. The Patent Cooperation Treaty permits Emerald to file Canadian and international versions of these US patent applications in 152 member countries worldwide over the coming year.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Its 50%-owned Pure Sunfarms in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Both facilities are in commercial production. It has also contracted for approximately 500 acres of hemp harvest in 2018 and 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Emerald Health Therapeutics’ Wholly Owned Subsidiary Northern Vine to Participate in Series of Cannabis Testing Seminars Hosted by Thermo Fisher Scientific

Source:  Emerald Health Therapeutics, Inc. 10/9/18

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Northern Vine Canada Inc. (Northern Vine), a wholly owned subsidiary of Emerald, will participate in an educational series  of seminars regarding cannabis testing solutions hosted by Thermo Fisher Scientific. Jaclyn Thomson, PhD, Director of R&D at Northern Vine, will provide a presentation on pesticide residue and terpenes analysis methods for the series, called: “Cannabis Testing One-Stop Analytical Solutions Seminar Series,” across Canada during October 9-18.

The seminar series will provide information to scientists establishing new cannabis testing laboratory or scaling-up operations. The series includes four stops in Montreal, Ottawa, Toronto, and Vancouver. Each seminar will cover: Health Canada regulation updates, targeted and non-targeted pesticide analysis, sample preparation tips for improving results, fast and accurate heavy metal analysis to ppb levels, rapid mycotoxin analysis, and cannabis potency testing.

“With nationwide legalization on the horizon, I’m honored to participate in this seminar series to share insights into how to comply with updated testing regulations for the Canadian cannabis market,” said Dr. Thomson. “The upcoming legal marketplace will create new opportunities for laboratories, licensed producers, and start-ups. Through this series, we hope to support and prepare these organizations to produce reliable results and ensure every sample meets regulated safety standards.”

For more information on Thermo Fisher Scientific’s complete cannabis testing solutions for the legalized Canadian market, please visit www.thermofisher.com/CannabisTesting.  

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC, and is in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility and is planning to add a 500,000 square foot greenhouse in Metro Vancouver. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

 

Emerald Health Therapeutics Signs Term Sheet to Access Large-Scale Extraction, Softgel Production, and New Product Development Capabilities Through Strategic Alliance with Factors Group of Nutritional Companies

Source:  Emerald Health Therapeutics, Inc. 8/27/18

Collaboration with natural health products leader positions Emerald with industry-leading manufacturing for value-added cannabis products, a significant growth opportunity in the legal medical and adult-use cannabis market

Emerald and Factors will also develop products supporting the endocannabinoid system for natural health products market

Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that it has signed a term sheet to form a strategic alliance with Factors R&D Technology, Inc. (“FTI”), a division of Factors Group of Nutritional Companies Inc. In this exclusive arrangement, FTI will provide to Emerald pharmaceutical-grade, industrial-scale manufacturing capacity as well as expertise in GMP-level extraction, softgel production, and packaging focused on the rapidly emerging market opportunities for medicinal cannabis in Canada and internationally. This collaboration leverages the Factors Group’s decades of experience in product development, formulation and innovation.

Factors Group is Canada’s largest nutritional supplement marketer and manufacturer and has over 1 million square feet of production facilities, R&D, and quality control laboratories and distribution centres. Factors Group has established deep roots and relationships in Canada and worldwide in the nutrition industry. Factors Group is unique in its vertically-integrated farm-to-retail supply chain abilities. FTI markets and sells its products under multiple brands.

Through this strategic alliance, FTI will initially provide Emerald with access to a facility with operating extraction infrastructure capable of processing up to 1 million kg of biomass annually and softgel production capacity of up to 600 million capsules per year. FTI will also provide technology transfer of its extraction methods and production protocols to allow Emerald to establish a future production and manufacturing facility closer to its cultivation facilities. Emerald has agreed to pay an initial $5 million fee to FTI to cover the costs of completing the unique extraction methods for Emerald, carrying out renovations necessary to comply with the Access to Cannabis for Medical Purposes Regulation (“ACMPR”), and the tech transfer.

“This strategic alliance with FTI will provide us industry leading expertise and capacity through FTI’s proprietary phytochemical extraction technology. Accessing FTI’s infrastructure will allow us to dramatically shorten our commercial  ramp-up from years to a few months, allowing us to leapfrog competitors attempting to build out their own extraction and encapsulation facilities,” said Dr. Avtar Dhillon, Executive Chairman of Emerald.

“We are activating multiple strategic options to ensure we have significant supply of raw cannabinoid inputs, and we now add FTI’s decades of experience in extracting bioactive compounds from plants in the highly regulated nutraceutical industry. With proven and reliable large-scale production of high-grade value-added cannabis products in place, we have significantly reduced the risks of scaling new manufacturing, quality assurance issues and product recalls that could be expected when going through such operational scaling and the associated learning curve. FTI gives us a distinct advantage in a market where rapid growth in consumer demand is expected to evolve toward high quality products that deliver precise, consistent dosing and other well-characterized attributes. This is a game-changer for Emerald, the Canadian medicinal cannabis industry and, most importantly, our customers.”

“We are scientifically, clinically, and ethically aligned with FTI and this alliance represents an ideal match,” said Chris Wagner, CEO of Emerald. “In the natural health products industry, FTI is unequivocally the largest and most experienced extractor of phyto-chemicals from plants in Canada. Working with one of the industry’s leaders to produce efficacious, high quality extraction-based products makes great business sense for us. In addition, our own marketing research identified that 60% of current legal cannabis users also use natural health products. This alliance will also allow us to strategically lay down valuable groundwork with product development and marketing initiatives that will uniquely position us to serve natural health product consumers.”

The term sheet also provides that FTI will enter into an exclusive agreement with Emerald Health Naturals (“EHN”), the joint venture of Emerald and Emerald Health Bioceuticals. This will enable the companies to collaborate on product innovation, marketing, and distribution strategies to provide a range of products containing cannabinoids, where legal, and other herbal formulations to support the human endocannabinoid system to the Canadian and global health products market. The collaboration will initially focus on manufacturing, distribution, and sales of EHN’s current product line.  As part of this arrangement, EHN will issue shares to FTI representing 25% of its issued share capital.

“As a naturopathic doctor, I have recommended FTI and its brands for decades because of their high integrity, focus on quality, extensive testing to assure label claims, and dedication to scientific research,” said Dr. Gaetano Morello, CEO of EHN.  “Having entrusted my patients to FTI products over the years, I am delighted to be joining forces to develop and sell additional products through FTI’s well-established sales channels and extensive shelf presence. We now have the near-term opportunity to offer new formulations and delivery approaches, including the use of softgels, with consistent, easy-to-consume doses of medicinal cannabinoids.”

FTI has been closely watching the development of the emerging medicinal cannabis sector. After careful consideration and market analysis, FTI is confident that Emerald is the leader in medicinal cannabis product development, that its commitment to high quality research in this field is unmatched, and that Emerald represents the best possible fit for FTI.

The term sheet is non-binding and the strategic alliance is subject to the negotiation and execution of definitive agreements. The strategic alliance and related activities are also subject to obtaining all necessary regulatory approvals.

About Factors R&D Technology, Inc. (FTI)

FTI is the research, development and technology subsidiary of Factors Group Inc.

About Factors Group Inc.

The Factors Group is Canada’s leader in the development, formulation and manufacture of nutritional supplements for the health products market. For more than 50 years, the company has supplied North American consumers with vitamin, mineral, herbal and specialty supplements.

The Factors Group has over 1 million square feet of manufacturing and production facilities, laboratories, distribution centers, and extensive warehouses. Its manufacturing capabilities include softgel and two-piece hard-shell encapsulation, tableting, liquid and powder extraction, multi-ingredient aqueous granulations, and a liquid fill line. The Factors Group sells its nutritional products in over 50 countries around the world.

The Factors Group is one of the only nutritional companies to have its own organic farms, its own extraction, encapsulation, and production facilities, its own labs and research facilities, and a vast network of academic, scientific, and retail partners.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is licensed in Canada to produce and sell dried cannabis and cannabis oil for medical purposes. Emerald is preparing to serve the fully legalized Canadian adult-use cannabis market starting October 17, 2018. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC and is now in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility and is planning to add a 500,000 square foot greenhouse in Metro Vancouver. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Emerald Health Therapeutics Announces Appointment of Pure Sunfarms President and CEO

Source:  Emerald Health Therapeutics, Inc. 8/21/18

Mandesh Dosanjh brings extensive consumer products experience with recent cannabis focus at Liquor Control Board of Ontario

Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (TSX:VFF) (OTC:VFFIF) today announced that Mandesh Dosanjh has been appointed President and Chief Executive Officer of Pure Sunfarms Corp., their 50/50 owned cannabis joint venture, effective on or before October 1, 2018. Mr. Dosanjh joins Pure Sunfarms from his position as Senior Vice President, Supply Chain and Wholesale, at the Liquor Control Board of Ontario (LCBO), where he led LCBO’s supply chain division, and developed and managed its supply chain and wholesale strategy as the LCBO prepared for the legalization of adult-use cannabis.

Mr. Dosanjh commented, “Over the past two years at the LCBO, I became immersed in the Canadian cannabis industry and gained an in-depth knowledge and understanding of its many suppliers. Pure Sunfarms truly stands out in the industry for both the experience and expertise of its team, and the quality of its growing operations, strongly positioning it for leadership in the adult-use market,” said Mr. Dosanjh. “I look forward to the opportunity to leverage my in-depth knowledge of the Canadian cannabis product landscape, as well as my many years managing consumer packaged goods supply chains, to drive the success of Pure Sunfarms as a fully integrated cannabis products business.”

“Mr. Dosanjh comes to Pure Sunfarms from a unique vantage point in the Canadian cannabis industry, and we expect his insights and relationships to be invaluable in growing the business,” said Mr. Chris Wagner, CEO, Emerald Health Therapeutics. “His broad experience will also be instrumental in driving efficiencies that will benefit bottom-line profit.”

“Mr. Dosanjh will be a tremendous asset to Pure Sunfarms as it moves aggressively to become a vertically integrated cannabis products supplier,” said Michael DeGiglio, CEO, Village Farms. “His deep experience in wholesale distribution and supply for large retailers, and intricate understanding of wholesale distribution in the Canadian cannabis industry, will provide Pure Sunfarms with a significant advantage in the development of its product and distribution strategy, as well as its brand and competitive positioning in the Canadian marketplace. In all respects, we are building this company the right way to drive sustainable value for the long term.”

Mr. Dosanjh is a seasoned supply chain executive with diverse industry experience. He has extensive experience planning and executing e-commerce, ERP, and logistics strategies focused on effectively and efficiently expanding business operations. His roles leading supply chains have provided him the opportunity to work closely with operations, quality control, IT, regulators, sales and marketing teams. As Senior Vice President, Supply Chain and Wholesale at LCBO, Mr. Dosanjh reported to the President and CEO. He was a member of the LCBO’s Executive Steering Committee for Cannabis, which provided guidance to the LCBO board of directors and Ontario government. Previously, Mr. Dosanjh held increasingly senior executive-level supply and distribution positions with a number of leading retailers, including Longo Brothers, Target Canada, Aritzia and Loblaw Companies.

About Village Farms International, Inc.

Village Farms International, Inc. is one of the largest and longest-operating vertically integrated greenhouse growers in North America and the only publicly traded greenhouse produce company in Canada. With more than 750 years of accumulated master grower experience coupled with advanced proprietary technology and environmentally sustainable growing practices, Village Farms is highly resource efficient. Village Farms produces and distributes fresh, premium-quality produce with consistency 365-days a year to national grocers in the U.S. and Canada from its large-scale Controlled Environment Agriculture (CEA) greenhouses in British Columbia and Texas, as well as from its partner greenhouses in BC, Ontario, and Mexico.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is licensed in Canada to produce and sell dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC and is now in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility and is planning to add a 500,000 square foot greenhouse in Metro Vancouver. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Emerald Health Therapeutics Completes Acquisition of Licensed Dealer Northern Vine Canada

Source:  Emerald Health Therapeutics, Inc. 8/15/18

Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (Emerald) has completed the purchase of the remaining shares of Northern Vine Canada Inc. (Northern Vine) from Abattis Bioceuticals Corp. (Abattis) (CSE: ATT; OTC: ATTBF) for $2 million in cash and 1,093,938 common shares of Emerald (with a deemed value of $4 million, based on the trailing 30 day VWAP of Emerald shares as of July 19, 2018). This transaction, announced on July 19^th, increases Emerald’s ownership of Northern Vine from 65% to 100%. Northern Vine is a Licensed Dealer (LD) under the provisions of the Canadian Controlled Drugs and Substances Act.

The dealer license allows Emerald to participate in the growing market for cannabis analytical testing, which Emerald expects to grow in conjunction with increasing cannabis production volumes in Canada. Northern Vine will operate independently of Emerald and is committed to serving all clients, including Licensed Producers and patient-growers. Legalization of cannabis for medical purposes and the upcoming legalization of cannabis for recreational purposes is expected to drive demand for analytical testing services to assess potency and concentration of toxic materials.

This acquisition also allows Emerald to leverage Northern Vine’s dealer license to advance research plans to develop cannabis formulations supporting new products for both recreational purposes and to treat a broad spectrum of human conditions and diseases.

The Agreement includes a milestone payment in the form of common shares of Emerald valued at $4 million if Northern Vine and/or Emerald receive gross revenue of $10 million from the sale of products or services introduced by Abattis.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald is preparing to serve the fully legalized Canadian adult-use cannabis market starting October 17, 2018. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC and is now in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility and is planning to add a 500,000 square foot greenhouse in Metro Vancouver. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.